IMS Health to acquire SDI

Share this article:

IMS Health will acquire SDI, bringing two of the largest data firms servicing the pharmaceutical industry together into one company. Financial terms of the deal were not disclosed.

Both companies declined to discuss the acquisition beyond a joint statement released last Friday afternoon. Unnamed company sources told Ed Silverman, who first reported the deal on his Pharmalot blog, that as much as 15% of SDI's staff could lose their jobs as a result of the acquisition.

“The addition of SDI's complementary information assets and capabilities positions IMS to improve existing offerings, fuel new investments and deliver greater innovation and value to a healthcare industry that is seeking to drive increased efficiencies as a result of significant, ongoing pressure to reduce costs and expand patient access,” the joint statement said.

Gary Gatyas, an IMS Health spokesperson, declined to speculate on timing for the completion of the deal, citing pre-merger notification requirements with respect to the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

SDI acquired Verispan in 2008, tripling its size in terms of workforce. Wolters Kluwer and Kantar Health were not immediately available to comment on ramifications of the acquisition.

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.